Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 25Small Cell Lung Carcinoma 23Leukemia 18Lymphoma, Large B-Cell, Diffuse 17Lung Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 14Lymphoma, Extranodal NK-T-Cell 11Hodgkin Disease 10Leukemia, Myeloid, Acute 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Neuroblastoma 7Lymphoma, Mantle-Cell 7Burkitt Lymphoma 7Recurrence 6Lymphoma, T-Cell, Peripheral 6Central Nervous System Neoplasms 6Retinoblastoma 5Lymphoma, Large-Cell, Immunoblastic 5Lymphohistiocytosis, Hemophagocytic 5Breast Neoplasms 5Testicular Neoplasms 4Multiple Myeloma 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Teratoma 3

Interventions

anlotinib 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Extensive Small Cell Lung Cancer × Etoposide × Clear all
NCT04234607 2020-01-22

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
738 enrolled
Thoracic

Extensive Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡